Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIA Study of UV1 Vaccination in Patients With Hormone-sensitive Metastatic Prostate Cancer

Trial Profile

A Phase I/IIA Study of UV1 Vaccination in Patients With Hormone-sensitive Metastatic Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2019

At a glance

  • Drugs UV 1 (Primary) ; Sargramostim
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms UV1hTERT2012P
  • Sponsors Ultimovacs AS
  • Most Recent Events

    • 06 May 2019 Planned End Date changed from 1 Jul 2020 to 1 Apr 2023.
    • 06 May 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Apr 2023.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top